Small Talk: Sinclair boosts portfolio with £21m Advanced Bio-Technologies deal

Sinclair Pharma and IS Pharma agreed to merge in April, with shares in the combined business (imaginatively christened Sinclair IS Pharma) starting trading in late May. Since then, the stock has been under pressure, easing as volatility in the wider market gathered pace. But the share price received a shot in the arm last week, after the company, which specialises in dermatological and wound care treatments, unveiled plans to buy the privately held US biotech company, Advanced Bio-Technologies (ABT).

The £21m cash and share deal, which has been structured to exclude ABT's US business, will boost Sinclair's suite of skincare products. The main offering is its Kelo-cote scar treatment, which will become Sinclair's second largest brand after Flammazine.

Sinclair gets ownership of the flagship (and high margin) product in all markets outside the US. Since it wasalready licensed for Kelo-cote in its core European markets, the deal opens up fast growing countries such as Brazil, Korea and China. In all, ABT's international business delivered revenues of $6.1m last year. That works out to growth of 19 per cent on the year before. And things are looking up.

"Based on the results in the first ten months of the current financial year to [the end of October], ABT's international revenues are expected to grow by approximately 40 per cent by the end of 2011, including revenues from Sinclair IS in Europe," the company said when it unveiled the deal on 8 December. Looking more closely at Kelo-cote, Sinclair said the treatment already has a foothold in Brazil, with the country, which will serve as a springboard for expansion into other Latin American markets, generating around $2m in revenues. On the other side of the world, in Asia, Kelo-cote boasts $1.1m in revenues in South Korea. It is also sold in other countries in the region, including China.

It's also worth noting that ABT has been pushing the treatment quite strongly in terms of marketing. This means that while Sinclair is looking to bolster the efforts, it will only need two additional staff to fulfil its ambitions in that regard.

The reaction in the markets was certainly positive, with the stock up 10 per cent since the announcement. The City was also welcoming. Pointing to Kelo-cote, Finncap analysts said the deal was essentially an "asset purchase". "We estimate that the incremental Kelo-cote revenues in the year ending June 2013 will be of the order of $8m," they said.

"This is a high gross margin product (we estimate more than 70 per cent) and the incremental costs (sales, marketing and shipping) we estimate will be about $1m... the net contribution to the bottom line will of the order of $4m."

Their counterparts at Singer Capital Markets added that the deal, which comes after Sinclair sold off its Mysoline epilepsy treatment, fitted with the company's strategy of focusing on its core areas.

"We note that the company has successfully recycled income from the divestment of Mysoline (a less attractive portfolio product) in order to fund this acquisition," Singer said.

Start your day with The Independent, sign up for daily news emails
News
ebookA unique anthology of reporting and analysis of a crucial period of history
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

SThree: Trainee Recruitment Consultant

£20000 - £25000 per annum + OTE £45K YR1: SThree: At SThree, we like to be dif...

SThree: Trainee Recruitment Consultant

£20000 - £25000 per annum + competitive: SThree: Did you know? SThree is a mul...

Guru Careers: C# Project Team Lead

£55 - 65k (DOE): Guru Careers: A unique opportunity for a permanent C# Develop...

Guru Careers: Graduate Editor / Editorial Assistant

£16 - 20k: Guru Careers: A Graduate Editor / Editorial Assistant is needed to ...

Day In a Page

Blundering Tony Blair quits as Middle East peace envoy – only Israel will miss him

Blundering Blair quits as Middle East peace envoy – only Israel will miss him

For Arabs – and for Britons who lost their loved ones in his shambolic war in Iraq – his appointment was an insult, says Robert Fisk
Fifa corruption arrests: All hail the Feds for riding to football's rescue

Fifa corruption arrests

All hail the Feds for riding to football's rescue, says Ian Herbert
Isis in Syria: The Kurdish enclave still resisting the tyranny of President Assad and militant fighters

The Kurdish enclave still resisting the tyranny of Assad and Isis

In Syrian Kurdish cantons along the Turkish border, the progressive aims of the 2011 uprising are being enacted despite the war. Patrick Cockburn returns to Amuda
How I survived Cambodia's Killing Fields: Acclaimed surgeon SreyRam Kuy celebrates her mother's determination to escape the US

How I survived Cambodia's Killing Fields

Acclaimed surgeon SreyRam Kuy celebrates her mother's determination to escape to the US
Stephen Mangan interview: From posh buffoon to pregnant dad, the actor has quite a range

How Stephen Mangan got his range

Posh buffoon, hapless writer, pregnant dad - Mangan is certainly a versatile actor
The ZX Spectrum has been crowd-funded back into play - with some 21st-century tweaks

The ZX Spectrum is back

The ZX Spectrum was the original - and for some players, still the best. David Crookes meets the fans who've kept the games' flames lit
Grace of Monaco film panned: even the screenwriter pours scorn on biopic starring Nicole Kidman

Even the screenwriter pours scorn on Grace of Monaco biopic

The critics had a field day after last year's premiere, but the savaging goes on
Menstrual Hygiene Day: The strange ideas people used to believe about periods

Menstrual Hygiene Day: The strange ideas people once had about periods

If one was missed, vomiting blood was seen as a viable alternative
The best work perks: From free travel cards to making dreams come true (really)

The quirks of work perks

From free travel cards to making dreams come true (really)
Is bridge the latest twee pastime to get hip?

Is bridge becoming hip?

The number of young players has trebled in the past year. Gillian Orr discovers if this old game has new tricks
Long author-lists on research papers are threatening the academic work system

The rise of 'hyperauthorship'

Now that academic papers are written by thousands (yes, thousands) of contributors, it's getting hard to tell workers from shirkers
The rise of Lego Clubs: How toys are helping children struggling with social interaction to build better relationships

The rise of Lego Clubs

How toys are helping children struggling with social interaction to build better relationships
5 best running glasses

On your marks: 5 best running glasses

Whether you’re pounding pavements, parks or hill passes, keep your eyes protected in all weathers
Joe Root: 'Ben Stokes gives everything – he’s rubbing off on us all'

'Ben Stokes gives everything – he’s rubbing off on us all'

Joe Root says the England dressing room is a happy place again – and Stokes is the catalyst
Raif Badawi: Wife pleads for fresh EU help as Saudi blogger's health worsens

Please save my husband

As the health of blogger Raif Badawi worsens in prison, his wife urges EU governments to put pressure on the Saudi Arabian royal family to allow her husband to join his family in Canada